imatinib, Gleevec

Pharmacy Author:
Medical and Pharmacy Editor:

GENERIC NAME: imatinib

BRAND NAME: Gleevec

DRUG CLASS AND MECHANISM: Imatinib is an oral medication used for treating chronic myeloid leukemia and acute lymphoblastic leukemia. It is classified as a kinase inhibitor. Kinase inhibitors include dasatinib (Sprycel), erlotinib (Tarceva), gefitinib (Iressa), nilotinib (Tasigna), pazopanib (Votrient), sunitinib (Sutent), and vandetanib (Caprelsa). Kinase inhibitors prevent tumors from growing by reducing the action of proteins that control cell division, growth and survival. These proteins are usually present in larger quantities or are more active in cancer cells. By reducing the activity of these proteins, growth and survival of cancer cells are reduced. The FDA approved imatinib in April 2003.

PRESCRIPTION: Yes

GENERIC AVAILABLE: Yes

PREPARATIONS: Tablets: 100, and 400 mg

STORAGE: Imatinib should be stored at room temperature between 15-30 C (59-86 F).

PRESCRIBED FOR: Imatinib is used for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome positive, chronic myeloid leukemia (Ph+ CML); treatment of Ph+ CML after failure of interferon-alpha therapy; adults with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL); adults with myeloproliferative or myelodysplastic diseases; mastocytosis; hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL); dermatofibrosarcoma protuberans; and gastrointestinal stromal tumors (GIST)




Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Pill Finder Tool

Need help identifying pills and medications?
Use the pill identifier tool on RxList.


Back to Medications Index